Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

The prognostic value of minimal residual disease (MRD) in Philadelphia-chromosome-positive (Ph+) childhood acute lymphoblastic leukemia (ALL) treated with tyrosine kinase inhibitors is not fully established. We detected MRD by real-time quantitative polymerase chain reaction (RQ-PCR) of rearranged i...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Haematologica
Main Authors: Cazzaniga, Giovanni, De Lorenzo, Paola, Alten, Julia, Röttgers, Silja, Hancock, Jeremy, Saha, Vaskar, Castor, Anders, Madsen, Hans O., Gandemer, Virginie, Cavé, Hélène, Leoni, Veronica, Köhler, Rolf, Ferrari, Giulia M., Bleckmann, Kirsten, Pieters, Rob, van der Velden, Vincent, Stary, Jan, Zuna, Jan, Escherich, Gabriele, zur Stadt, Udo, Aricò, Maurizio, Conter, Valentino, Schrappe, Martin, Valsecchi, Maria Grazia, Biondi, Andrea
Formato: Artigo
Idioma:Inglês
Publicado: Ferrata Storti Foundation 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5777198/
https://ncbi.nlm.nih.gov/pubmed/29079599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.176917
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares